Vaxcyte director granted options for 26,061 shares

Vaxcyte, Inc. director Moncef Slaoui reported receiving a new stock option grant covering 26,061 shares of common stock.

Rhea-AI Filing Summary

Vaxcyte, Inc. director Moncef Slaoui reported receiving a new stock option grant covering 26,061 shares of common stock. The option has an exercise price of $52.11 per share and expires on June 22, 2036.

The award was granted at no cost and is classified as a compensation-related grant, not an open‑market purchase or sale. According to the vesting terms, one‑third of the option will vest on June 17, 2027, with the remaining portion vesting in equal monthly installments over the following 24 months, contingent on his continued service with the company.

Insider Trade Summary

Grant/Award: 26,061 shares

Grant/Award 1 txn

Insider Slaoui Moncef

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	26,061	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 26,061 contracts (Direct)

Footnotes (1)

1. F1. Option shall vest over 36 months, 1/3 of which will vest on June 17, 2027 and 1/36 of which will vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.

Key Figures

Option grant size: 26,061 shares Exercise price: $52.11 per share Expiration date: June 22, 2036 +3 more

6 metrics

Option grant size 26,061 shares Stock Option (right to buy) underlying common stock

Exercise price $52.11 per share Conversion or exercise price of stock option

Expiration date June 22, 2036 Option expiration date

Shares after grant 26,061 derivative securities Total options following this transaction

Initial cliff vesting 1/3 on June 17, 2027 First vesting tranche of option grant

Ongoing vesting schedule 1/36 monthly thereafter Remaining vesting over next 24 months

Key Terms

Stock Option (right to buy), Common Stock, Grant, award, or other acquisition, expiration date, +1 more

5 terms

Stock Option (right to buy) financial

"The security is listed as a "Stock Option (right to buy)" tied to common stock."

Common Stock financial

"The underlying security title for the option is identified as "Common Stock.""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Grant, award, or other acquisition financial

"The transaction code description states "Grant, award, or other acquisition" for this option."

expiration date financial

"The option carries an expiration date of June 22, 2036 for exercising rights."

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest monthly financial

"One thirty‑sixth of the option will vest monthly after June 17, 2027, subject to continued service."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Vaxcyte (PCVX) report for Moncef Slaoui?

Vaxcyte reported that director Moncef Slaoui received a grant of stock options for 26,061 shares of common stock. The options are a compensation award, not an open‑market trade, and give him the right to buy shares at a fixed exercise price if they vest.

What is the exercise price of Moncef Slaoui’s new Vaxcyte (PCVX) stock options?

The new stock options granted to Moncef Slaoui have an exercise price of $52.11 per share. This means he can purchase Vaxcyte common stock at that price once the options vest, regardless of the market price at that future time.

How do the newly granted Vaxcyte (PCVX) stock options vest for Moncef Slaoui?

The option vests over 36 months. One‑third of the award vests on June 17, 2027, and the remaining two‑thirds vest in equal monthly installments thereafter, provided Slaoui continues to serve Vaxcyte through each vesting date.

When do Moncef Slaoui’s Vaxcyte (PCVX) stock options expire?

The reported stock option grant to Moncef Slaoui expires on June 22, 2036. After that date, any unexercised portion of the 26,061‑share option will lapse, and he will no longer be able to purchase shares under this specific award.

Is Moncef Slaoui’s Vaxcyte (PCVX) option grant a market purchase or sale?

The filing classifies the transaction as a grant or award acquisition, not a market buy or sell. Slaoui received the option at no cost as part of compensation, and no open‑market purchase or sale of common stock was reported in this transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2026 - 04:30 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Slaoui Moncef

(Last) (First) (Middle)

C/O VAXCYTE, INC.

825 INDUSTRIAL ROAD, SUITE 300

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$52.11	06/22/2026		A		26,061		(1)	06/22/2036	Common Stock	26,061	$0	26,061	D

Explanation of Responses:

1. Option shall vest over 36 months, 1/3 of which will vest on June 17, 2027 and 1/36 of which will vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.

Remarks:

	Moncef Slaoui, by /s/ Peter N. Efremenko, Attorney-In-Fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)